Table 4.

Treatment of MetS with risk of PD conversion.

	PD free n = 278	PD conversion n = 181	Adjusted HR (95% CI)&
Treatment of MetS components#
3-4 components, n (%)	72 (25.9)	31 (17.1)	0.62 (0.45–0.97)*
2 components, n (%)	103 (37.1)	50 (27.6)	0.68 (0.48–0.99)*
1 component, n (%)	71 (25.5)	53 (29.3)	1.18 (0.72–1.68)
None treatment, n (%)	32 (11.5)	47 (26.0)	2.70 (1.64–4.43)**

CI, confidence interval; HDL-C, high density lipoprotein cholesterol; HR, hazard ratio; MetS, metabolic syndrome; PD, Parkinson's disease.

^&The model is adjusted for age, daily drinking, current smoking, metabolic syndrome, and WMHs.

^#Patients with metabolic syndrome were treated with high blood pressure, high fasting plasma glucose, hypertriglyceridemia, and low HDL-C, excluding central obesity. Three-component therapy, two-component therapy, and one-component therapy refer to three, two or one of the four components of high blood pressure, high fasting plasma glucose, hypertriglyceridemia, and low HDL-C.

^* P < 0.05;

^**P < 0.01.